FDA warns Shionogi over postmarketing studies; billionaire Singh brothers prepared to fight Daiichi;

 @FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma

 @EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce

> The FDA has sent a notice to Japanese drugmaker Shionogi for the failing to do required postmarketing studies on its pain drug Rybix ODT. Story

> The FDA said it has approved COBAS INTEGRA 800 Tina-quant HbA1cDx assay as the first HbA1c test for the diagnosis of diabetes. Announcement

>  The World Health Organization (WHO) has warned countries with possible cases of the SARS-like novel coronavirus that the need to share information on the lethal virus. Story

> Under pressure from activist hedge fund manager Bill Ackman, Procter & Gamble has replaced Chairman and CEO Bob McDonald with its former CEO A.G. Lafley. Story

Medical Device News

 @FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev

 @MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce

 @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce

> Ethicon study asserts safety of medical-grade polycarbonate devices. Story

> Covidien, Kona Medical trumpet new tech at EuroPCR. More

> Covidien's board approves pharma spinoff. Article

Biotech News

 @FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce

 @RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce

> Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma. Article

> Pfizer denies knowledge of acquired companies' failures in East German drug trials. Story

> Merck Serono CEO stakes out Boston biotech startups. More

And Finally... The billionaire Singh brothers have the will and the way to fight Japanese drugmaker Daiichi Sankyo, who this week said it might sue them for allegedly covering up the problems at Ranbaxy Laboratories when they sold controlling interest to the company in 2008. Story

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.